94% of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatment. Mean factor IX activity levels were sustained at near normal levels of 37% through four years post-treatment, reinforcing the efficacy of HEMGENIX® in the treatment of haemophilia B.
Helena Bragd is the new General Manager of CSL Behring Nordic Region – Sweden, Denmark, Norway, Finland, and Iceland. CSL Behring is a global biotherapeutics leader driven by our promise to save lives.
CSL Behring Denmark today announced that the first Danish patients with haemophilia B were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec). HEMGENIX® is the first one-time gene therapy to be approved in Europe for the treatment of adults with severe and moderately severe haemophilia B.
CSL Behring today announced that an outcome-based agreement has been reached with Amgros, the Danish procurement authority, for the national reimbursement of HEMGENIX® in Denmark. Denmark is the first country in the Nordic region to reimburse HEMGENIX® under such a performance-based model, in which the regions only incur costs if the gene therapy proves effective over an agreed long-term period.
CSL Behring today announced that a positive recommendation for reimbursement of HEMGENIX has been released by the Danish Medicines Council for the treatment of patients with rare blood clotting disorder, haemophilia B opening the way to finalize a commercial contract with Amgros, the Danish procurement authority.1 Denmark is the first country in the Nordics to reimburse HEMGENIX.
Den 17 april är det Världshemofilidagen som i år har fokus på rättvis tillgång till behandling för alla med blödarsjuka. CSL Behring är ett globalt bioteknikföretag som drivs av löftet att rädda och förbättra människors liv. Forskningen inom hemofili har gjort stora framsteg under de senaste åren som har lett till nya behandlingsformer.
These regulatory milestones bring CSL one step closer to delivering on our promise to patients with a first-in-class recombinant monoclonal antibody for people living with HAE, a community CSL has been serving for over 40 years, in the US and European Union.
